Today: 24 April 2026
AppLovin stock price rises again as UBS trims target and earnings loom
10 February 2026
2 mins read

AppLovin stock price rises again as UBS trims target and earnings loom

New York, Feb 10, 2026, 17:24 ET — Trading after hours

  • AppLovin climbed 2.7% to $472.92 Tuesday, notching a second straight day of gains.
  • UBS trimmed its price target but stuck with a Buy, pointing to ad results from AppLovin’s Axon system.
  • The company will announce its quarterly results after the U.S. market shuts on Wednesday.

AppLovin Corp (APP.O) climbed 2.7% to $472.92 in after-hours action on Tuesday, building on a two-day rally before its quarterly earnings. Earlier, shares moved between $462.13 and $479.67, with roughly 6.1 million shares traded during regular hours.

Timing’s a factor here. AppLovin is set to deliver results after Wednesday’s close, and lately the stock’s been reacting sharply to a stream of analyst notes and quick-fire responses, beyond just moves in the broader market.

UBS cut its price target on AppLovin to $686 from $840 on Tuesday, sticking with its Buy call. The bank cited stronger fourth-quarter ad budgets and improved “return on ad spend” connected to AppLovin’s Axon 2.0. UBS flagged rising competitive threats, mentioning Meta’s push back into gaming ads and potential longer-term disruption from Alphabet’s Project Genie. As for Unity, UBS described its progress as more restrained. TipRanks

The rally actually kicked off the previous day. On Monday, shares soared over 13% after CapitalWatch took to social media with a correction and apology, stating it was “formally retracting” certain allegations against shareholder Tang Hao. An internal probe had determined its claims linking him to criminal groups failed the outlet’s standards. CapitalWatch added it held no financial stake in AppLovin, and said the retraction wouldn’t alter its broader position. AppLovin, for its part, had sent a cease-and-desist letter last month, calling for the withdrawal. Investopedia

Jefferies’ James Heaney is sticking with his Buy call and $860 target, shrugging off the stock’s 39% slide so far this year. On Monday, Heaney called it “a great buying opportunity,” downplaying concerns tied to CloudX, Meta Audience Network, and Google Genie as “overblown risks.” Heaney sees a “significant revenue beat” for the fourth quarter, according to his analysis. Investing.com

AppLovin, which provides software for app developers and advertisers to manage ad buying and placement, has positioned Axon as its solution for automating targeting and bidding. Investors want to see proof that ad performance remains solid—and that e-commerce spending has room to keep growing.

AppLovin plans to report both its fourth-quarter and full-year 2025 earnings once U.S. trading wraps up on Feb. 11, the company said. CEO Adam Foroughi and CFO Matthew Stumpf will lead a webcast at 5 p.m. ET.

But there’s risk on both sides. Disappointing results, or even a cautious tone—especially after bullish research has already shifted expectations—could see the move reverse just as quickly, sending shares right back where they started in a week.

Sentiment shocks remain a core risk here. The stock’s history includes sudden swings after external commentary. Competitive pressure isn’t letting up either, with larger platforms and fresh players continually entering the field.

Wednesday’s report is up next, with the earnings call tone likely to matter just as much. Traders are set to parse guidance, watching for concrete signs of how AppLovin aims to hold advertiser interest straight through 2026.

Stock Market Today

  • State Street EVP Michael Richards Sells 3,000 Shares Amid Solid Earnings
    April 24, 2026, 5:30 PM EDT. Michael Richards, Executive Vice President of State Street Corporation (NYSE:STT), sold 3,000 shares at an average price of $153.89, totaling $461,670 on April 22. Post-sale, Richards owns 43,522 shares, down 6.45%. State Street stock dipped 0.4% to $150.69 with a market cap of $41.75 billion. The company reported strong Q1 earnings on April 17, with EPS of $2.84 beating estimates by $0.20 and 15.6% revenue growth year-over-year. A quarterly dividend of $0.84 per share was paid on April 13, providing a 2.2% yield. Institutional investors continue adjusting holdings, with MIRAE ASSET GLOBAL ETFS and NewEdge Advisors increasing stakes recently.

Latest article

Magnachip Semiconductor Stock Jumps 23% as New BatteryFET Puts Q1 Earnings in Focus

Magnachip Semiconductor Stock Jumps 23% as New BatteryFET Puts Q1 Earnings in Focus

24 April 2026
Magnachip Semiconductor’s U.S.-listed shares jumped 23% late Friday to $5.25 ahead of its April 28 earnings report. The company this week launched two 8th-generation 12V MOSFETs for smartphone battery protection, with one already in mass production for a major global smartphone maker. Magnachip has guided for Q1 revenue of $44–$48 million and a gross margin of 14–16%. Analysts expect a loss of 22 cents per share.
HCA Healthcare Stock Drops Despite Profit Beat As Weak Volumes Rattle Investors

HCA Healthcare Stock Drops Despite Profit Beat As Weak Volumes Rattle Investors

24 April 2026
HCA Healthcare shares dropped 8.8% to $432.46 after first-quarter profit narrowly beat estimates but showed weaker patient volumes and payer-mix concerns. Revenue rose 4.3% to $19.1 billion, net income hit $1.62 billion, and adjusted EBITDA climbed 1.9% to $3.8 billion. Respiratory admissions fell 42% year-over-year. HCA reaffirmed its 2026 financial guidance.
Morgan Stanley stock slides as AI tax tool spooks wealth managers
Previous Story

Morgan Stanley stock slides as AI tax tool spooks wealth managers

Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive
Next Story

Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive

Go toTop